Cargando…
Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period
BACKGROUND/PURPOSE OF THE STUDY: Tumor heterogeneity based on copy number variations is associated with the evolution of cancer and its clinical grade. Clonal composition (CC) represents the number of clones based on the distribution of B-allele frequency (BAF) obtained from a genome-wide single nuc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843910/ https://www.ncbi.nlm.nih.gov/pubmed/34973129 http://dx.doi.org/10.1007/s12072-021-10278-4 |
_version_ | 1784651367628931072 |
---|---|
author | Kaibori, Masaki Sakai, Kazuko Matsushima, Hideyuki Kosaka, Hisashi Matsui, Kosuke De Velasco, Marco A. Sekimoto, Mitsugu Nishio, Kazuto |
author_facet | Kaibori, Masaki Sakai, Kazuko Matsushima, Hideyuki Kosaka, Hisashi Matsui, Kosuke De Velasco, Marco A. Sekimoto, Mitsugu Nishio, Kazuto |
author_sort | Kaibori, Masaki |
collection | PubMed |
description | BACKGROUND/PURPOSE OF THE STUDY: Tumor heterogeneity based on copy number variations is associated with the evolution of cancer and its clinical grade. Clonal composition (CC) represents the number of clones based on the distribution of B-allele frequency (BAF) obtained from a genome-wide single nucleotide polymorphism (SNP) array. A higher CC number represents a high degree of heterogeneity. We hypothesized and evaluated that the CC number in hepatocellular carcinoma (HCC) tissues might be associated with the clinical outcomes of patients. METHODS: Somatic mutation, whole transcriptome, and CC number based on copy number variations of 36 frozen tissue samples of operably resected HCC tissues were analyzed by targeted deep sequencing, transcriptome analysis, and SNP array. RESULTS: The samples were classified into the heterogeneous tumors as poly-CC (n = 26) and the homogeneous tumors as mono-CC (n = 8). The patients with poly-CC had a higher rate of early recurrence and a significantly shorter recurrence-free survival period than the mono-CC patients (7.0 months vs. not reached, p = 0.0084). No differences in pathogenic non-synonymous mutations, such as TP53, were observed between the two groups when targeted deep sequencing was applied. A transcriptome analysis showed that cell cycle-related pathways were enriched in the poly-CC tumors, compared to the mono-CC tumors. Poly-CC HCC is highly proliferative and has a high risk of early recurrence. CONCLUSION: CC is a possible candidate biomarker for predicting the risk of early postoperative recurrence and warrants further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10278-4. |
format | Online Article Text |
id | pubmed-8843910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer India |
record_format | MEDLINE/PubMed |
spelling | pubmed-88439102022-02-23 Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period Kaibori, Masaki Sakai, Kazuko Matsushima, Hideyuki Kosaka, Hisashi Matsui, Kosuke De Velasco, Marco A. Sekimoto, Mitsugu Nishio, Kazuto Hepatol Int Original Article BACKGROUND/PURPOSE OF THE STUDY: Tumor heterogeneity based on copy number variations is associated with the evolution of cancer and its clinical grade. Clonal composition (CC) represents the number of clones based on the distribution of B-allele frequency (BAF) obtained from a genome-wide single nucleotide polymorphism (SNP) array. A higher CC number represents a high degree of heterogeneity. We hypothesized and evaluated that the CC number in hepatocellular carcinoma (HCC) tissues might be associated with the clinical outcomes of patients. METHODS: Somatic mutation, whole transcriptome, and CC number based on copy number variations of 36 frozen tissue samples of operably resected HCC tissues were analyzed by targeted deep sequencing, transcriptome analysis, and SNP array. RESULTS: The samples were classified into the heterogeneous tumors as poly-CC (n = 26) and the homogeneous tumors as mono-CC (n = 8). The patients with poly-CC had a higher rate of early recurrence and a significantly shorter recurrence-free survival period than the mono-CC patients (7.0 months vs. not reached, p = 0.0084). No differences in pathogenic non-synonymous mutations, such as TP53, were observed between the two groups when targeted deep sequencing was applied. A transcriptome analysis showed that cell cycle-related pathways were enriched in the poly-CC tumors, compared to the mono-CC tumors. Poly-CC HCC is highly proliferative and has a high risk of early recurrence. CONCLUSION: CC is a possible candidate biomarker for predicting the risk of early postoperative recurrence and warrants further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-021-10278-4. Springer India 2022-01-01 /pmc/articles/PMC8843910/ /pubmed/34973129 http://dx.doi.org/10.1007/s12072-021-10278-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Kaibori, Masaki Sakai, Kazuko Matsushima, Hideyuki Kosaka, Hisashi Matsui, Kosuke De Velasco, Marco A. Sekimoto, Mitsugu Nishio, Kazuto Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period |
title | Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period |
title_full | Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period |
title_fullStr | Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period |
title_full_unstemmed | Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period |
title_short | Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period |
title_sort | patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843910/ https://www.ncbi.nlm.nih.gov/pubmed/34973129 http://dx.doi.org/10.1007/s12072-021-10278-4 |
work_keys_str_mv | AT kaiborimasaki patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod AT sakaikazuko patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod AT matsushimahideyuki patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod AT kosakahisashi patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod AT matsuikosuke patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod AT develascomarcoa patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod AT sekimotomitsugu patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod AT nishiokazuto patientswithpolyclonalhepatocellularcarcinomaareatahighriskofearlyrecurrenceandhaveapoorrecurrencefreesurvivalperiod |